Librela 3 years post launch; what do we know now?

Librela® was launched in 2021 and since then millions of dogs globally with osteoarthritis have benefited from this innovative monoclonal antibody therapy. This presentation will include safety and efficacy data from real world usage of Librela® and discuss how it is best used in practice to optimise outcomes for your osteoarthritic patients.

Learning Outcomes
• Gain insight into real world study data concerning usage, quality of life improvements and treatment compliance with Librela® • Understand the pharmacovigilance process and SPC updates • Understand the importance of the multimodal approach for patients with osteoarthritis
Speakers: Jayne Clark, National Veterinary Manager Pain portfolio - Zoetis UK

15 Nov 2024
12:30 - 13:15
Platinum Suite - Level 3

Presented at London Vet Show 2024

Please note this session is not RACE-approved but you can still earn a CPD certificate